You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中恒集團(600252.SH):子公司擬受讓取得一種治療慢性心力衰竭的藥物技術
格隆匯 08-04 18:51

格隆匯8月4日丨中恒集團(600252.SH)公佈,為契合公司發展戰略,持續優化與延伸產品管線,公司全資子公司中恒創新擬受讓取得中國人民解放軍海軍軍醫大學持有的一種治療慢性心力衰竭的藥物技術(專利權)。根據上海技術交易所2025年5月20日發佈的掛牌公吿,該項目掛牌轉讓底價為人民幣5,500.00萬元,保證金為人民幣50.00萬元,本次轉讓掛牌結束日期為2025年6月18日。該項目的轉讓總價由首付款與里程碑付款構成。其中,首付款不少於500.00萬元,需於《技術(專利權)轉讓合同》生效之日起10個工作日內支付至轉讓方指定銀行賬户,後續里程碑付款在相對應的里程碑事件發生後10個工作日內予以支付;具體節點與條件以合同約定為準。2025年6月20日,中恒創新收到上海技術交易所出具的《受讓資格確認通知書》《組織簽約通知》,確認中恒創新為“一種治療慢性心力衰竭的藥物”的受讓方。成交價格為人民幣5,500.00萬元。2025年8月1日,中恒創新與中國融通科研院簽訂《技術(專利權)轉讓合同》。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account